BackIdorsia Overview

Idorsia EBIT

Idorsia's EBIT is $-150M, below the Healthcare sector average of $99B.

Get informed when a big investor buys or sells

+ Follow

Quarterly EBIT

-$34.87M
↑ 55.86% YoY

As of Sep 30, 2026

Annual EBIT (TTM)

-$153.60M
↓ 79.52% YoY

Trailing 12 months ending Sep 30, 2026

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

Idorsia (IDIA.SW) FAQ

The latest EBIT for IDIA.SW is $-150M as of September 2026. That compares with $-86M in the prior-year period — down 79.5% year over year. That is below the Healthcare sector average of $99B. Investors often review this figure alongside Idorsia's historical trend and sector peers before judging valuation or financial health.

Over the past year, IDIA.SW's EBIT moved from $-86M to $-150M — a 79.5% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Idorsia's operating scale or balance-sheet position.

Against Healthcare companies, IDIA.SW currently prints $-150M for EBIT, while the sector average sits near $99B. That is roughly 100.2% below the sector mean. Large gaps often invite a closer look at Idorsia's growth, margins, and balance sheet.

A EBIT figure of $-150M for IDIA.SW is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $99B. Explore the charts below for those layers of context.

After noting IDIA.SW's EBIT ($-150M), review year-over-year change from $-86M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.